CTLA4 and melanoma: Enrichment of clonal neoantigens in lesions enhanced the sensitivity of patients with NSCLC or melanoma to anti‐PD‐1 and anti‐CTLA‐4 therapy and promoted overall survival in patients with lung adenocarcinomas.31